Significant reduction in key neurodegeneration biomarker correlated with treatment response, suggesting neflamapimod may act on underlying disease CervoMed preparing to initiate Phase 3 registrational ...

Neflamapimod is an oral p38 alpha kinase inhibitor that targets dysfunction and degeneration of acetylcholine-producing ...

Please provide your email address to receive an email when new articles are posted on . In this video, James E. Galvin, MD, MPH, discusses the SHIMMER study, presented at the Alzheimer’s Association ...

(RTTNews) - CervoMed Inc. (CRVO) has announced positive 32-week data from the Extension phase of its phase IIb RewinD-LB trial of oral investigational drug Neflamapimod for the treatment of dementia ...

Share on Pinterest A new drug candidate called SAK3 successfully stopped the progression of a form of dementia in mice. Jacek Kadaj/Getty Images A drug candidate called SAK3 prevented further loss of ...

New research suggests that two proteins, amyloid- and phosphorylated tau, the key proteins of Alzheimer's disease, are detected in blood once symptoms have started in Lewy's body diseases, such as ...

Alzheimer’s disease is the most commonly diagnosed form of dementia, but it’s far from the only one. In fact, most people who ...

Lewy body dementia (LBD) is a type of progressive disease that has affected more than a million Americans, according to the Lewy Body Dementia Association. Over time, it destroys brain cells and can ...

While Alzheimer’s disease is the most common type of dementia, there’s another variation that is also relatively prevalent. Lewy body dementia (LBD) affects more than 1 million people in the US. It is ...

Q: I have heard that Parkinson’s disease and Lewy body dementia are related. What exactly is Lewy body dementia? A: Lewy Body Dementia (LBD) is a brain disease that's cause is unknown. Protein ...

Results from a new study reinforce the notion that dementia with Lewy bodies can be pathologically classified into two different disease types. Results obtained in a study recently completed at the ...

Early detection of Alzheimer’s disease-related changes in Parkinson's disease and dementia with Lewy bodies could be made possible by monitoring the amyloid-β (Aβ) and phosphorylated tau (p-tau) ...